Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

By E. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S. Sedlacek, B. Fisher, D. Wickerham, G. Yothers, A. Soran, N. Wolmark. Journal of Clinical Oncology, 2005

727 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/930ae56eb8acdcda23092086b083a8292b6815b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Richard J. Jones
2. A. Emadi
3. R. Brodsky

Citations in the corpus

• Cyclophosphamide and cancer: golden anniversary (2009, background): “The addition of a sequential taxane to this adjuvant regimen further improved outcomes and has since become the standard of care for human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer”